SYSTEM AND METHODS FOR USING A DYNAMIC SCHEME FOR RADIOSURGERY
    352.
    发明申请
    SYSTEM AND METHODS FOR USING A DYNAMIC SCHEME FOR RADIOSURGERY 有权
    用于放射治疗的动态方案的系统和方法

    公开(公告)号:US20140107394A1

    公开(公告)日:2014-04-17

    申请号:US14107541

    申请日:2013-12-16

    Applicant: STC.UNM

    Abstract: The present invention is a method and system for developing a dynamic scheme for Gamma Knife radiosurgery based on the concept of “dose-painting” to take advantage of robotic patient positioning systems on the Gamma Knife C and Perfexion units. The spherical high dose volume created by the Gamma Knife unit will be viewed as a 3D spherical “paintbrush”, and treatment planning is reduced to finding the best route of this “paintbrush” to “paint” a 3D tumor volume. Under the dose-painting concept, Gamma Knife radiosurgery becomes dynamic, where the patient is moving continuously under the robotic positioning system.

    Abstract translation: 本发明是基于“剂量绘画”的概念,利用伽玛刀C和Perfexion单元上的机器人患者定位系统开发伽玛刀放射外科手术的动态方案和系统。 由伽玛刀单元创建的球形高剂量体积将被视为3D球形“画笔”,并且减少治疗计划以找到该“画笔”最佳路线来“绘制”3D肿瘤体积。 在剂量绘画概念下,伽玛刀放射外科手术变得动态,病人在机器人定位系统下连续移动。

    Nanocrystalline optically-based neutron irradiation history sensor
    353.
    发明授权
    Nanocrystalline optically-based neutron irradiation history sensor 有权
    纳米晶体光子中子辐射历史传感器

    公开(公告)号:US08680469B1

    公开(公告)日:2014-03-25

    申请号:US13385457

    申请日:2012-02-21

    CPC classification number: G01T3/00

    Abstract: A neutron irradiation history sensor and detection method for detection of thermal neutrons exploit transmutation of 164Dy into 165Ho and 166Er and significant differences in optical properties of Dy, Ho, and Er in order to enable detection of relative fractions of Dy, Ho, and Er and thus the degree and timing of prior thermal neutron exposure that has occurred, providing a tamper-proof forensic record of the prior thermal neutron exposure. The irradiation history sensor and detection method advantageously employ Dy-containing nanocrytals (NCs) residing in a transparent host.

    Abstract translation: 用于探测热中子的中子辐射历史传感器和检测方法利用164Dy的转变为165Ho和166Er,并且Dy,Ho和Er的光学性质有显着差异,以便能够检测Dy,Ho和Er的相对分数, 因此已经发生了先前的热中子暴露的程度和时间,提供了先前的热中子暴露的防篡改取证记录。 照射历史传感器和检测方法有利地使用驻留在透明主体中的含Dy纳米颗粒(NC)。

    Modulators of GTPase and Use In Relevant Treatment
    356.
    发明申请
    Modulators of GTPase and Use In Relevant Treatment 有权
    GTPase调节剂和相关治疗用途

    公开(公告)号:US20130345277A1

    公开(公告)日:2013-12-26

    申请号:US13867658

    申请日:2013-04-22

    Abstract: The present invention relates to molecules which function as selective modulators of the Ras-homologous (Rho) family of small GTPases, in particular, Cdc42 GTPase and their use to treat diseases, for example cancers, including metastatic cancer, genetic and acquired diseases where activation of Cdc42 GTPase plays a pivotal role, such as neurodegenerative diseases, rheumatoid arthritis, atherosclerosis, diabetes type I, autosomal polycystic kidney disease, cystic kidney disease, precystic kidney disease, microbial infections, including Chlamydia infections, E. coli infections, H. pylori infections and its secondary effects including gastric ulcers, Coxiella Brunetti (Q-fever) infections and Streptococcus pneumonia infections, fungal infections including Paracoccidiodes brasiliensis and Candida albicans and their secondary effects including lung edema. Additionally, compounds according to the present invention may be used to inhibit rejection in transplant patients (pursuant to transplantation), to promote immunosuppression, anti-inflammatory response and to mobilize stem cell (migration) in patients in need, among others.

    Abstract translation: 本发明涉及用作小GTP酶的Ras同源(Rho)家族,特别是Cdc42GTP酶的选择性调节剂的分子及其用于治疗疾病的用途,例如癌症,包括转移性癌症,遗传和获得性疾病,其中激活 的Cdc42 GTPase起着关键的作用,如神经退行性疾病,类风湿关节炎,动脉粥样硬化,I型糖尿病,常染色体多囊肾病,囊性肾病,前期肾脏疾病,微生物感染,包括衣原体感染,大肠杆菌感染,幽门螺杆菌 感染及其次要作用包括胃溃疡,布氏梭菌(Qex fever)感染和肺炎链球菌感染,包括巴西隐孢子虫和白色念珠菌在内的真菌感染及其副作用,包括肺水肿。 此外,根据本发明的化合物可以用于抑制移植患者的排斥(根据移植),以促进免疫抑制,抗炎反应和在需要的患者中调动干细胞(迁移)等。

    Compounds and methods for use in diagnosing and treating melanoma, including metastatic melanoma and methods related to same
    357.
    发明授权
    Compounds and methods for use in diagnosing and treating melanoma, including metastatic melanoma and methods related to same 有权
    用于诊断和治疗黑素瘤的化合物和方法,包括转移性黑素瘤及与其相关的方法

    公开(公告)号:US08603435B2

    公开(公告)日:2013-12-10

    申请号:US12811946

    申请日:2009-01-12

    Abstract: The present invention is directed to novel non-invasive diagnostic tools/compounds comprising a cyclic peptide wherein the compound binds to a MSH receptor to image and treat cancers, especially, melanoma, including metastatic melanoma in vivo. The present invention represents a clear advance in the art which presently relies on tissue biopsy for diagnoses of these cancers. The novel imaging probes are capable of detecting cancerous melanoma cells, as well as their metastatic spread in tissues. The present invention represents a step forward in the diagnosis and treatment of melanoma, including metastatic melanoma using non-invasive molecular imaging techniques. The novel probes of the present invention are also useful to initiate therapy for melanoma as well as monitor patients response to chemotherapy treatments and other interventions or therapies used in the treatment of melanoma/metastatic melanoma. Compounds according to the present invention may be used as diagnostic tools for a number of conditions and diseases states as well as therapeutic agents for treating such conditions and disease states.

    Abstract translation: 本发明涉及包含环肽的新型非侵入性诊断工具/化合物,其中所述化合物结合MSH受体以在体内成像和治疗癌症,特别是黑素瘤,包括转移性黑素瘤。 本发明代表了目前依赖于组织活检以诊断这些癌症的本领域的明显进步。 新型成像探针能够检测癌细胞黑素瘤细胞,以及它们在组织中的转移扩散。 本发明代表使用非侵入性分子成像技术在黑色素瘤的诊断和治疗中包括转移性黑素瘤的进展。 本发明的新型探针也可用于引发黑素瘤的治疗以及监测患者对化疗治疗的反应和用于治疗黑素瘤/转移性黑色素瘤的其它干预或治疗。 根据本发明的化合物可以用作许多病症和疾病状态的诊断工具以及用于治疗这些病症和疾病状态的治疗剂。

    SWELLABLE PARTICLES FOR DRUG DELIVERY
    358.
    发明申请
    SWELLABLE PARTICLES FOR DRUG DELIVERY 审中-公开
    用于药物递送的易碎颗粒

    公开(公告)号:US20130323310A1

    公开(公告)日:2013-12-05

    申请号:US13866764

    申请日:2013-04-19

    Applicant: STC.UNM

    Abstract: Swellable particles for delivering a working agent to the pulmonary system comprise a plurality of biodegradable particles each formed from a polymer network, each of the plurality of biodegradable particles having a mass mean aerodynamic diameter not exceeding 5 μm, the particles being swellable by hydration to a size that is greater than 6 μm volume mean diameter, and a working agent entrapped in the polymer network of each of the plurality of biodegradable particles.

    Abstract translation: 用于将工作剂递送到肺系统的可溶胀颗粒包括多个可生物降解的颗粒,每个由聚合物网络形成,所述多个可生物降解的颗粒中的每一个具有不超过5μm的质量平均空气动力学直径,所述颗粒可以通过水合膨胀至 尺寸大于6μm体积平均直径,以及包埋在多个生物可降解颗粒中的每一个的聚合物网络中的工作剂。

    AEROSOL REDUCTION/EXPANSION SYNTHESIS (A-RES) FOR ZERO VALENT METAL PARTICLES
    359.
    发明申请
    AEROSOL REDUCTION/EXPANSION SYNTHESIS (A-RES) FOR ZERO VALENT METAL PARTICLES 有权
    用于零价金属颗粒的气溶胶还原/扩展合成(A-RES)

    公开(公告)号:US20130276583A1

    公开(公告)日:2013-10-24

    申请号:US13884746

    申请日:2011-11-10

    Abstract: Various embodiments provide methods of forming zero valent metal particles using an aerosol-reductive/expansion synthesis (A-RES) process. In one embodiment, an aerosol stream including metal precursor compound(s) and chemical agent(s) that produces reducing gases upon thermal decomposition can be introduced into a heated inert atmosphere of a RES reactor to form zero valent metal particles corresponding to metals used for the metal precursor cot pound(s).

    Abstract translation: 各种实施方案提供了使用气溶胶 - 还原/扩展合成(A-RES)方法形成零价金属颗粒的方法。 在一个实施方案中,包含金属前体化合物和在热分解时产生还原气体的化学试剂的气溶胶流可引入到RES反应器的加热惰性气氛中,以形成对应于用于 金属前体婴儿床。

    Compounds for binding to ER alpha/beta and GPR30, methods of treating disease states and conditions mediated through these receptors and identification thereof
    360.
    发明授权
    Compounds for binding to ER alpha/beta and GPR30, methods of treating disease states and conditions mediated through these receptors and identification thereof 有权
    用于结合ERα/β和GPR30的化合物,治疗通过这些受体介导的疾病状态和病症的方法及其鉴定

    公开(公告)号:US08487100B2

    公开(公告)日:2013-07-16

    申请号:US12967871

    申请日:2010-12-14

    CPC classification number: C07D221/16 C07D405/04 C07D405/14

    Abstract: The current invention is in the field of molecular biology/pharmacology and provides compounds which modulate the effects of GPR30 as well as the classical estrogen receptors alpha and beta (ERα and ERβ). These compounds may function as agonists and/or antagonists of one or more of the disclosed estrogen receptors. Diseases which are mediated through one or more of these receptors include cancer (particularly breast, reproductive and other hormone-dependent cancers, leukemia, colon cancer, prostate cancer), reproductive (genito-urological) including endometreitis, prostatitis, polycystic ovarian syndrome, bladder control, hormone-related disorders, hearing disorders, cardiovascular conditions including hot flashes and profuse sweating, hypertension, stroke, obesity, osteoporosis, hematologic diseases, vascular diseases or conditions such as venous thrombosis, atherosclerosis, among numerous others and disorders of the central and peripheral nervous system, including depression, insomnia, anxiety, multiple sclerosis, neuropathy, neurodegenerative disoders such as Parkinson's disease and Alzheimer's disease, as well as inflammatory bowel disease, Crohn's disease, coeliac (celiac) disease and related disorders of the intestine. A contraceptive indication to prevent or reduce the likelihood of pregnancy after intercourse is a further aspect of the present invention.

    Abstract translation: 本发明在分子生物学/药理学领域,并提供调节GPR30以及经典雌激素受体α和β(ERα和ERβ)的作用的化合物。 这些化合物可以用作一种或多种所公开的雌激素受体的激动剂和/或拮抗剂。 通过这些受体中的一种或多种介导的疾病包括癌症(特别是乳腺,生殖和其他激素依赖性癌症,白血病,结肠癌,前列腺癌),生殖(泌尿 - 泌尿)包括子宫内膜炎,前列腺炎,多囊卵巢综合征,膀胱 控制,激素相关疾病,听觉障碍,心血管疾病,包括潮热和大量出汗,高血压,中风,肥胖,骨质疏松症,血液病,血管疾病或诸如静脉血栓形成,动脉粥样硬化等疾病,以及许多其他疾病和中枢和 周围神经系统,包括抑郁症,失眠,焦虑,多发性硬化,神经病变,神经变性解码器如帕金森病和阿尔茨海默病,以及炎性肠病,克罗恩病,腹腔(腹腔)疾病和肠道相关疾病。 用于预防或减少性交后怀孕的可能性的避孕指示是本发明的另一方面。

Patent Agency Ranking